比瑞那帕

Birinapant

未知生产厂商

Birinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Birinapant has been investigated for the treatment of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).

技术标识符

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

IAP binding compounds
US 9394249 B2申请人: TETRALOGIC PHARM CORP优先权: 2014
US
2 件公开
Dimeric IAP inhibitors
US 9187490 B2申请人: TETRALOGIC PHARM CORP优先权: 2014
US
2 件公开
SMAC Mimetic
US 10034912 B2申请人: TETRALOGIC BIRINAPANT UK LTD优先权: 2016
US
2 件公开
SMAC MIMETIC (BIRINAPANT) FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES (CANCER)
US 2014243276 A1申请人: WENG DAVID优先权: 2012
US
COMBINATION THERAPY
WO 2016079527 A1申请人: TETRALOGIC BIRINAPANT UK LTD优先权: 2014
WO
BIRINAPANT POLYMORPH H
US 20250304635 A1申请人: MEDIVIR AB优先权: 2023
US